More about

Thyroid Eye Disease

News
December 13, 2019
4 min read
Save

FDA committee unanimously recommends approval of teprotumumab for thyroid eye disease

FDA committee unanimously recommends approval of teprotumumab for thyroid eye disease

The Dermatologic and Ophthalmic Drugs Advisory Committee of the FDA voted 12-0 Friday in favor of recommending approval of a biologics license application for teprotumumab, an experimental human monoclonal antibody shown to dramatically reduce the most debilitating symptoms of Graves’ orbitopathy.

News
December 01, 2019
1 min read
Save

Recent FDA actions you may have missed

Recent FDA actions you may have missed

Endocrine Today has compiled a list of recent FDA news stories relating to endocrine practice. Drugs under consideration included those for thyroid eye disease, diabetes, hypertriglyceridemia, Prader-Willi syndrome and nonalcoholic steatohepatitis.

News
November 10, 2019
1 min read
Save

Top takeaways from ATA

Endocrine Today has compiled a list of the top five news reports posted from the American Thyroid Association Annual Meeting, held from Oct. 30 to Nov. 3 in Chicago.

News
November 02, 2019
5 min watch
Save

VIDEO: Research highlights from ATA

VIDEO: Research highlights from ATA

CHICAGO — In this video exclusive, Endocrine Today Editorial Board Member Stephanie L. Lee, MD, PhD, FACE, ECNU, professor of medicine and director of thyroid health in the section of endocrinology, diabetes and nutrition at Boston Medical Center, discusses four important studies presented at the American Thyroid Association Annual Meeting.

News
November 02, 2019
5 min read
Save

Researcher highlights new treatments for thyroid eye disease

Researcher highlights new treatments for thyroid eye disease

CHICAGO — Thyroid eye disease, a condition most commonly associated with Graves’ hypothyroidism, typically comes with a range of symptoms that can make everyday tasks challenging and quickly reduce quality of life. Within 18 months of a diagnosis of Graves’ disease, approximately 80% of patients will develop thyroid eye disease, with symptoms including proptosis, the main cause or morbidity, as well as eyelid retraction, strabismus and compressive optic neuropathy.

News
October 31, 2019
2 min read
Save

Symptoms, quality of life improve with teprotumumab for adults with thyroid eye disease

CHICAGO — Among adults with recent-onset thyroid eye disease, those who received the monoclonal human antibody teprotumumab experienced substantial symptom relief and reported quality of life gains compared with those assigned placebo, according to pooled data from a phase 2 and a phase 3 clinical trial of the drug presented at the American Thyroid Association annual meeting.

News
October 22, 2019
1 min read
Save

Two subtypes distinguish ophthalmic Graves’ disease

SAN FRANCISCO — Rather than thinking of ophthalmic Graves’ disease as one entity classified as “mild” or “moderate to severe,” William R. Nunery, MD, FACS, told colleagues at the American Society of Ophthalmic Plastic and Reconstructive Surgery meeting that thyroid eye disease should be considered as two separate subtypes.

News
September 09, 2019
1 min read
Save

FDA prioritizes thyroid eye disease medication review

The FDA on Monday granted priority review of the investigational medication teprotumumab for treatment of thyroid eye disease, also known as Graves’ orbitopathy according to a press release from Horizon Therapeutics.

View more